2 results
Approved WMOCompleted
Part 1: To assess the safety and effectiveness of subcutaneous golimumab 50 mg (SC-GLM50), administered by autoinjection once monthly during 6 months, when combined with different DMARD regimens used in daily rheumatology. Part 2: In subjects who…
Approved WMOCompleted
This study is not intended to improve your health, but is necessary for the further development of RO7034067 .The study will be performed in 3 parts, Parts 1, 2 and 3. This document only refers to Part 1/2/3 of the study . Part 1:A single dose will…